{"preliminary_commentary":{"by_channel":{"x_thread":10,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05433142\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"XmAb819-01","nct_id":"NCT05433142","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=xmab819-01-nct05433142. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose Escalation will establish the dosing schedule for XmAb819 administered IV and the dosing schedule of XmAb819 administered SC. The dosing schedule includes the priming dose, step-up priming dose(s), the minimum safe and biologically active dose.\n\nDose Expansion may administer XmAb819 IV, and XmAb819 SC.","label":"Dose Escalation and Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":307,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"XmAb819","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-08-03","lead_sponsor":"Xencor, Inc.","official_title":"A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)","timeFrame":"28 days"},{"measure":"Incidence of dose limiting toxicities (DLTs)","timeFrame":"28 days"}],"references":[],"start_date":{"date":"2022-06-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05433142"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/xmab819-01-nct05433142"}